Document is current

Article History

Received: 22 May 2023

Accepted: 4 August 2023

First Online: 21 August 2023

Declarations

:

: Human postmortem brain tissues from amygdala, hippocampus, and frontal cortex were provided by the Mayo Clinic Florida Brain Bank. Diagnosis was independently ascertained by trained neurologists and neuropathologists upon neurological and pathological examinations, respectively. All participants, or the next of kin, provided written informed consent, and all protocols were reviewed and approved by the Mayo Clinic Institutional Review Board and Ethics Committee.

: All authors have reviewed the final manuscript and consent to publication.

: BFB receives institutional research grant support from Alector, Biogen, Transposon, Cognition Therapeutics, and GE Healthcare. BFB receives honorarium for SAB activities for the Tau Consortium. LP is a consultant for Expansion Therapeutics. DSK serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study. DSK served on a Data Safety monitoring Board for a tau therapeutic for Biogen (until 2021) but received no personal compensation. DSK is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. DSK has served as a consultant for Roche, Samus Therapeutics, Magellan Health, Biovie and Alzeca Biosciences but receives no personal compensation. DSK attended an Eisai advisory board meeting for lecanemab on December 2, 2022, but received no compensation. DSK receives funding from the NIH. All other authors declare no disclosures or conflicts of interest related to the content of the article.